World's Best Scientists 2026 revealed!
Award Badge
Medicine
South Africa
2025

D-Index & Metrics

Medicine

D-Index
124
Citations
107231
World Ranking
3145
National Ranking
131

Research.com Recognitions

  • 2025 - Research.com Medicine in South Africa Leader Award
  • 2023 - Research.com Medicine in South Africa Leader Award
  • 2022 - Research.com Medicine in South Africa Leader Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Myocardial infarction
  • Surgery

His main research concerns Internal medicine, Myocardial infarction, Stroke, Randomized controlled trial and Surgery. His biological study spans a wide range of topics, including Placebo, Endocrinology and Cardiology. His work deals with themes such as Epidemiology, Heart failure and Emergency medicine, which intersect with Myocardial infarction.

His Stroke research focuses on subjects like Atrial fibrillation, which are linked to Heart rate. His study in Randomized controlled trial is interdisciplinary in nature, drawing from both Anesthesia and Confidence interval. His Surgery study combines topics from a wide range of disciplines, such as Warfarin and Risk factor.

His most cited work include:

  • Apixaban versus Warfarin in Patients with Atrial Fibrillation (5705 citations)
  • Apixaban in Patients with Atrial Fibrillation (1891 citations)
  • Predictors of hospital mortality in the global registry of acute coronary events. (1578 citations)

What are the main themes of his work throughout his whole career to date?

His scientific interests lie mostly in Internal medicine, Cardiology, Stroke, Myocardial infarction and Epidemiology. His research on Internal medicine frequently connects to adjacent areas such as Surgery. In general Cardiology, his work in ST elevation, Coronary artery disease and Ejection fraction is often linked to In patient linking many areas of study.

As a part of the same scientific family, Alvaro Avezum mostly works in the field of Stroke, focusing on Aspirin and, on occasion, Rivaroxaban. His Myocardial infarction study incorporates themes from Odds ratio and Risk factor. His Epidemiology research is multidisciplinary, relying on both Gerontology, Environmental health, Diabetes mellitus, Disease and Prospective cohort study.

He most often published in these fields:

  • Internal medicine (51.99%)
  • Cardiology (28.48%)
  • Stroke (24.83%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (51.99%)
  • Epidemiology (16.56%)
  • Randomized controlled trial (15.56%)

In recent papers he was focusing on the following fields of study:

Alvaro Avezum mainly focuses on Internal medicine, Epidemiology, Randomized controlled trial, Stroke and Prospective cohort study. The Internal medicine study combines topics in areas such as Placebo and Cardiology. He has researched Epidemiology in several fields, including Diabetes mellitus, Cohort study, Family medicine and Environmental health.

His study in the fields of Clinical endpoint under the domain of Randomized controlled trial overlaps with other disciplines such as Hydroxychloroquine. Alvaro Avezum has included themes like Renal function, Heart failure, Atrial fibrillation and Risk factor in his Stroke study. The various areas that Alvaro Avezum examines in his Prospective cohort study study include Incidence, Blood lipids, Disease, Vascular disease and Cohort.

Between 2018 and 2021, his most popular works were:

  • Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial (593 citations)
  • Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. (383 citations)
  • Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. (227 citations)

Best Publications

  • Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

    Salim Yusuf;Steven Hawken;Stephanie Ôunpuu;Tony Dans

  • Apixaban versus Warfarin in Patients with Atrial Fibrillation

    Christopher B. Granger;John H. Alexander;Renato D. Lopes;Elaine M. Hylek

  • Apixaban in Patients with Atrial Fibrillation

    Stuart J. Connolly;John Eikelboom;Campbell Joyner;Hans-Christoph Diener

  • Predictors of hospital mortality in the global registry of acute coronary events.

    Christopher B. Granger;Robert J. Goldberg;Omar Dabbous;Karen S. Pieper

  • Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.

    P J Devereaux

  • Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.

    Sanjit S Jolly;Salim Yusuf;John Cairns;Kari Niemelä

  • Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

    John W. Eikelboom;Stuart J. Connolly;Jackie Bosch;Gilles R. Dagenais

  • Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries

    Clara K. Chow;Clara K. Chow;Koon K. Teo;Sumathy Rangarajan;Shofiqul Islam

  • Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study

    Martin J O'Donnell;Martin J O'Donnell;Siu Lim Chin;Sumathy Rangarajan;Denis Xavier

  • A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry

    Kim A Eagle;Michael J Lim;Omar H Dabbous;Karen S Pieper

  • Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)

    Keith A A Fox;Omar H Dabbous;Robert J Goldberg;Karen S Pieper

  • Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study

    Salim Yusuf;Philip Joseph;Sumathy Rangarajan;Shofiqul Islam

  • Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study

    Darryl P Leong;Darryl P Leong;Koon K Teo;Koon K Teo;Sumathy Rangarajan;Patricio Lopez-Jaramillo

  • Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

    R. S. McKelvie;S. Yusuf;D. Pericak;A. Avezum

  • Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study

    Mahshid Dehghan;Andrew Mente;Andrew Mente;Xiaohe Zhang;Sumathi Swaminathan

  • The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study

    Scott A Lear;Weihong Hu;Sumathy Rangarajan;Danijela Gasevic

  • Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

    James J Ferguson;Robert M Califf;Elliott M Antman;Marc Cohen

  • Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey

    Salim Yusuf;Shofiqul Islam;Clara K Chow;Sumathy Rangarajan

  • Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.

    Bruno M Tomazini;Israel S Maia;Alexandre B Cavalcanti;Otavio Berwanger

  • Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.

    Alexandre B. Cavalcanti;Fernando G. Zampieri;Regis G. Rosa;Luciano C.P. Azevedo

Frequent Co-Authors

Salim Yusuf
Salim Yusuf McMaster University
Patricio López-Jaramillo
Patricio López-Jaramillo University of Santander
Rafael Diaz
Rafael Diaz University of Alberta
Koon K. Teo
Koon K. Teo McMaster University
Annika Rosengren
Annika Rosengren Sahlgrenska University Hospital
Gilles R. Dagenais
Gilles R. Dagenais Université Laval
Sumathy Rangarajan
Sumathy Rangarajan Population Health Research Institute
Rajeev Gupta
Rajeev Gupta Rajasthan University of Health Sciences
Keith A.A. Fox
Keith A.A. Fox University of Edinburgh
Renato D. Lopes
Renato D. Lopes Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in healthcare doesn’t always mean attending medical school. There are a variety of online degrees and credentials that can open doors to well-paying roles in the medical field.

For those interested in the administrative side, exploring online medical billing and coding can provide specialized skills to work in healthcare offices, insurance companies, and hospitals.

Nursing remains in high demand, and many accredited programs now offer flexibility to start or advance your nursing education remotely. If you’re aiming to become a nurse, discover what is the cheapest online college for nursing? to maximize affordability and access.

For licensed nurses seeking advanced practice roles, there are options for further specialization. You can compare programs based on cost and value, with practical guides such as the cheapest online acute care nurse practitioner programs.

Ambitious professionals can also pursue terminal degrees without giving up their careers. Several online phd programs nursing are available, providing flexible ways to lead, teach, or conduct research in healthcare.

Best Scientists Citing Alvaro Avezum

Trending Scientists